I appreciate the feedback & will keep it in mind w
Post# of 148235
(Total Views: 473)
Posted On: 05/27/2022 3:42:01 AM
I appreciate the feedback & will keep it in mind when making posts.
> in this post: https://investorshangout.com/post/view?id=6410425
I justified the reasons why I felt doubling the dose would at least double the effect. Only small losses in body weight, 5, 7 & 10%, led to huge changes in classification of NAS scores.
> In this post: https://investorshangout.com/post/view?id=6410338
I was making an analogy by comparing the BBB to a filter which allowed certain size particles, proteins, cells to pass. I didn't say it was that precisely. I was conjecturing that in an inflamed state, the BBB would allow fewer particles to pass into the brain because the holes would clog. However, ohm explained that the cytokines of IL6 and IL 1 actually cause the BBB to fall apart to some degree thereby permitting larger particles in.
> on your 3rd critique, you're right, I should have just stated it plainly. Scar tissue & fibrotic tissue is dead. There is no blood supply. Therefore, why do the macrophages not eradicate it? Because their CCR5 receptors are full of CCL5 convincing them they are self and not foreign. Got to get rid of the CCL5 and replace with LL to get rid of the dead stuff. I'm not making light of this.
> On Alzheimer's, and the use of MRI to assess LL effectiveness, I brought up this: https://www.imperial.nhs.uk/consultant-directory/paul-edison
as Paul Edison is our new expert on neurological disorders. I was trying to point to the good possibility that he would advise on the use of MRI to assess the effectiveness of LL in Alzheimer's which is what Recknor is doing in NASH using MRI markers cT1 and PDFF. "His research has focused on neuroimaging with novel molecular probes, using PET and magnetic resonance techniques for imaging pathophysiological changes associated with Alzheimer's disease, Parkinson's disease, and other neurodegenerative diseases." I didn't say it can measure plaques and tau, I said he will likely recommend pursuing this path.
> I don't believe I said the last point you made.
Thanks for your feedback. Will keep it in mind and will adjust my writing style.
> in this post: https://investorshangout.com/post/view?id=6410425
I justified the reasons why I felt doubling the dose would at least double the effect. Only small losses in body weight, 5, 7 & 10%, led to huge changes in classification of NAS scores.
> In this post: https://investorshangout.com/post/view?id=6410338
I was making an analogy by comparing the BBB to a filter which allowed certain size particles, proteins, cells to pass. I didn't say it was that precisely. I was conjecturing that in an inflamed state, the BBB would allow fewer particles to pass into the brain because the holes would clog. However, ohm explained that the cytokines of IL6 and IL 1 actually cause the BBB to fall apart to some degree thereby permitting larger particles in.
> on your 3rd critique, you're right, I should have just stated it plainly. Scar tissue & fibrotic tissue is dead. There is no blood supply. Therefore, why do the macrophages not eradicate it? Because their CCR5 receptors are full of CCL5 convincing them they are self and not foreign. Got to get rid of the CCL5 and replace with LL to get rid of the dead stuff. I'm not making light of this.
> On Alzheimer's, and the use of MRI to assess LL effectiveness, I brought up this: https://www.imperial.nhs.uk/consultant-directory/paul-edison
as Paul Edison is our new expert on neurological disorders. I was trying to point to the good possibility that he would advise on the use of MRI to assess the effectiveness of LL in Alzheimer's which is what Recknor is doing in NASH using MRI markers cT1 and PDFF. "His research has focused on neuroimaging with novel molecular probes, using PET and magnetic resonance techniques for imaging pathophysiological changes associated with Alzheimer's disease, Parkinson's disease, and other neurodegenerative diseases." I didn't say it can measure plaques and tau, I said he will likely recommend pursuing this path.
> I don't believe I said the last point you made.
Thanks for your feedback. Will keep it in mind and will adjust my writing style.
(7)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼